Loading...

We've got a brand new version of Simply Wall St! Try it out

Rapid Dose Therapeutics

CNSX:DOSE
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DOSE
CNSX
CA$53M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to improve patient outcomes in Canada. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
DOSE Share Price and Events
7 Day Returns
-1.4%
CNSX:DOSE
0.7%
North America Life Sciences
1.3%
CA Market
1 Year Returns
-
CNSX:DOSE
9.9%
North America Life Sciences
-0.1%
CA Market
DOSE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Rapid Dose Therapeutics (DOSE) -1.4% -6.7% 1.4% - - -
North America Life Sciences 0.7% 4.1% -3.2% 9.9% 75% 115.1%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on DOSE.
  • No trading data on DOSE.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Rapid Dose Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Rapid Dose Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is CA$0.7.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Rapid Dose Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Rapid Dose Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:DOSE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-05-31) in CAD CA$-0.18
CNSX:DOSE Share Price ** CNSX (2019-09-20) in CAD CA$0.7
North America Life Sciences Industry PE Ratio Median Figure of 21 Publicly-Listed Life Sciences Companies 36.07x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Rapid Dose Therapeutics.

CNSX:DOSE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:DOSE Share Price ÷ EPS (both in CAD)

= 0.7 ÷ -0.18

-3.97x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rapid Dose Therapeutics is loss making, we can't compare its value to the North America Life Sciences industry average.
  • Rapid Dose Therapeutics is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Rapid Dose Therapeutics's expected growth come at a high price?
Raw Data
CNSX:DOSE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.97x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Life Sciences Industry PEG Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 3.05x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Rapid Dose Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Rapid Dose Therapeutics's assets?
Raw Data
CNSX:DOSE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-05-31) in CAD CA$0.04
CNSX:DOSE Share Price * CNSX (2019-09-20) in CAD CA$0.7
North America Life Sciences Industry PB Ratio Median Figure of 42 Publicly-Listed Life Sciences Companies 4.66x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:DOSE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:DOSE Share Price ÷ Book Value per Share (both in CAD)

= 0.7 ÷ 0.04

17.6x

* Primary Listing of Rapid Dose Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rapid Dose Therapeutics is overvalued based on assets compared to the North America Life Sciences industry average.
X
Value checks
We assess Rapid Dose Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Rapid Dose Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Rapid Dose Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rapid Dose Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.8%
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Rapid Dose Therapeutics expected to grow at an attractive rate?
  • Unable to compare Rapid Dose Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Rapid Dose Therapeutics's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Rapid Dose Therapeutics's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:DOSE Future Growth Rates Data Sources
Data Point Source Value (per year)
North America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.8%
North America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:DOSE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:DOSE Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-05-31 0 -3 -14
2019-02-28 -2 -11
2018-11-30 0 -1 -3
2018-08-31 -1 -2
2018-02-28 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Rapid Dose Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Rapid Dose Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:DOSE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Rapid Dose Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:DOSE Past Financials Data
Date (Data in CAD Millions) EPS *
2019-05-31 -0.18
2019-02-28 -0.18
2018-11-30 -0.07
2018-08-31 -0.07
2018-02-28 -0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Rapid Dose Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Rapid Dose Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Rapid Dose Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Rapid Dose Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Rapid Dose Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the North America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the North America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Rapid Dose Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Rapid Dose Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Rapid Dose Therapeutics's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Rapid Dose Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Rapid Dose Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Rapid Dose Therapeutics's 1-year growth to the North America Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Rapid Dose Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Rapid Dose Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:DOSE Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-05-31 0.02 -14.17 5.68 0.25
2019-02-28 -11.40 2.90 0.22
2018-11-30 0.00 -3.03 2.49 0.45
2018-08-31 -2.44 2.03 0.39
2018-02-28 -1.80 1.51 0.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Rapid Dose Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Rapid Dose Therapeutics has efficiently used its assets last year compared to the North America Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Rapid Dose Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Rapid Dose Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Rapid Dose Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Rapid Dose Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Rapid Dose Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Rapid Dose Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Rapid Dose Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Rapid Dose Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Rapid Dose Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Rapid Dose Therapeutics Company Filings, last reported 3 months ago.

CNSX:DOSE Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-05-31 3.01 0.00 1.99
2019-02-28 3.83 0.00 3.49
2018-11-30 5.72 0.00 4.37
2018-08-31 6.73 0.00 6.04
2018-02-28 0.59 0.00 0.33
  • Rapid Dose Therapeutics has no debt.
  • Rapid Dose Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Rapid Dose Therapeutics has less than a year of cash runway based on current free cash flow.
  • Rapid Dose Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 128.2% each year.
X
Financial health checks
We assess Rapid Dose Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Rapid Dose Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Rapid Dose Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Rapid Dose Therapeutics dividends.
If you bought CA$2,000 of Rapid Dose Therapeutics shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Rapid Dose Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Rapid Dose Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:DOSE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 0.4%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Rapid Dose Therapeutics has not reported any payouts.
  • Unable to verify if Rapid Dose Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Rapid Dose Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Rapid Dose Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Rapid Dose Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Rapid Dose Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Rapid Dose Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Rapid Dose Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Upsdell
COMPENSATION CA$412,211
CEO Bio

Mr. Mark Andrew Upsdell is the Chief Executive Officer and Director of Rapid Dose Therapeutics Corp. and also serves as President. Mr. Upsdell leads RDT – Rapid Dose Therapeutics, with a unique combination of global business and technology transformational growth experience. His ability to build high-performance growth oriented teams, including his strategically-selected executive management staff, has served as a growth catalyst to drive revenue results. He believes in innovation, strategy and people. He was Senior Global Manager of Strategy and Planning at Cisco, and held director positions within Cisco and Hewlett Packard.

CEO Compensation
  • Insufficient data for Mark to compare compensation growth.
  • Mark's remuneration is lower than average for companies of similar size in Canada.
Management Team

Mark Upsdell

TITLE
President
COMPENSATION
CA$412K

Jason Lewis

TITLE
Senior VP of Business Development & Director
COMPENSATION
CA$192K

Ian Fodie

TITLE
Chief Financial Officer
AGE
55
TENURE
0.4 yrs

Kristina Shea

TITLE
Marketing & Communications Director

Jorge Estepa

TITLE
Assistant Corporate Secretary
Board of Directors

Mark Upsdell

TITLE
President
COMPENSATION
CA$412K

Jason Lewis

TITLE
Senior VP of Business Development & Director
COMPENSATION
CA$192K

Brian Howlett

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
05. Apr 19 Sell Brian Howlett Individual 04. Apr 19 04. Apr 19 -2,500 CA$0.78 CA$-1,950
X
Management checks
We assess Rapid Dose Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Rapid Dose Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Do Directors Own Rapid Dose Therapeutics Corp. (CNSX:DOSE) Shares?

As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Rapid Dose Therapeutics is not a large company by global standards. … Check out our latest analysis for Rapid Dose Therapeutics CNSX:DOSE Ownership Summary, May 9th 2019 What Does The Lack Of Institutional Ownership Tell Us About Rapid Dose Therapeutics? … Insider Ownership Of Rapid Dose Therapeutics The definition of an insider can differ slightly between different countries, but members of the board of directors always count.

Simply Wall St -

Company Info

Description

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to improve patient outcomes in Canada. The company’s over the counter products include QuickStrip, a processed oral film that contains the active molecule embedded in the delivery matrix; QuickStrip energy; vitamin B12; and QuickStrip sleep that delivers melatonin to your system. It also PharmaStrip delivery system. The company serves pharmaceutical and healthcare manufacturing industry. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.

Details
Name: Rapid Dose Therapeutics Corp.
DOSE
Exchange: CNSX
Founded:
CA$52,514,928
75,021,327
Website: http://www.rapid-dose.com
Address: Rapid Dose Therapeutics Corp.
1121 Walkers Line,
Burlington,
Ontario, L7N 2G4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX DOSE Common Shares Canadian National Stock Exchange CA CAD 17. Dec 2018
Number of employees
Current staff
Staff numbers
0
Rapid Dose Therapeutics employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:41
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/07/29
Last earnings reported: 2019/05/31
Last annual earnings reported: 2019/02/28


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.